A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.235 enrolled

Overview

The purpose of the study was an Open Label Extension to the recurrence prevention study to evaluate long-term safety and tolerability of paliperidone ER in subjects with schizophrenia.

The primary objective of the open-label extension was the long-term assessment of safety and tolerability of ER OROS paliperidone 3 to 15 mg/day in subjects diagnosed with schizophrenia. In addition, the long-term efficacy and effect of ER OROS paliperidone on overall functioning and personal and social functioning, as well as quality of life, health economics, and subjective sleep measures, was explored. This open-label extension study followed a recurrence prevention study (R076477-SCH-301) that had both an open-label run-in/stabilization phase and a double-blind, placebo-controlled phase. Open-label study drug (ER OROS paliperidone 3 mg to 15 mg/day) was administered for 52 weeks.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

235

Conditions

Schizophrenia

Interventions

Extended Release OROS® PaliperidoneDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects who had experienced a recurrence event during the double blind phase of Study R076477-SCH-301 * Remained recurrence free until the end of the double-blind phase, or were in the run-in or stabilization phases when the study was terminated * Who signed the informed consent for the open-label extension * And who the investigator agreed that open-label treatment was in the best interest of the subject were eligible to participate in the open-label extension Exclusion Criteria: * Not eligible to enter the open-label phase if believed to be at significant risk for suicidal or violent behavior during the open-label extension trial * Were pregnant or had received an injection of a depot antipsychotic since entry into the preceding double-blind phase

Outcomes

Primary Outcomes

Long-term assessment of safety and tolerability of ER OROS paliperidone 3 to 15 mg/day in subjects diagnosed with schizophrenia

Secondary Outcomes

Long-term efficacy and effect of ER OROS paliperidone on overall functioning and personal and social functioning, quality of life, health economics, and subjective sleep measures

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.